US aims to tighten rules on direct-to-consumer drug ads

267 With a new Congress controlled by the Democratic Party, the US biotech industry might be facing tighter restrictions on direct-toconsumer (DTC) advertising. This spring, Congress is set to debate measures that include a two-year moratorium on advertising for newly approved products and higher user fees for extra Food and Drug Administration (FDA) staff… CONTINUE READING